St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Pediatr Blood Cancer. 2010 Apr;54(4):649-51. doi: 10.1002/pbc.22378.
We summarize data presented on the use of high-dose chemotherapy (HDCT) with stem cell rescue for patients with recurrent medulloblastoma and other primitive neuroectodermal tumors as presented at an international consensus and state of the art workshop held in Milan in 2006. Eight, mainly institutional, studies were presented that included 159 patients who received HDCT of whom 22% were disease-free survivors at the time of reporting. Of those receiving HDCT and who relapsed having received previous radiotherapy, 17.3% were disease-free survivors at the time of reporting. However, from the two national studies that reported results from the time of relapse, only 4.2% were event free survivors. The outlook for previously irradiated patients with recurrent PNETs remains extremely poor and more effective therapeutic approaches are needed.
我们总结了 2006 年在米兰举行的国际共识和最新进展研讨会上提出的关于使用高剂量化疗（HDCT）和干细胞挽救治疗复发性髓母细胞瘤和其他原始神经外胚层肿瘤患者的数据。会上提出了八项主要的机构研究，其中包括 159 名接受 HDCT 的患者，其中 22%的患者在报告时为无病幸存者。在接受 HDCT 并在之前接受过放疗后复发的患者中，17.3%的患者在报告时为无病幸存者。然而，从两项报告复发时结果的全国性研究来看，只有 4.2%的患者无事件生存。以前接受过放疗的复发性 PNET 患者的预后仍然非常差，需要更有效的治疗方法。
